This study and others3,24, have also demonstrated that carriers of pathogenic RAD51C/D mutations tend to develop triple-negative breast cancers, in contrast to the predominantly (4 of 5 cases) hormone receptor-positive breast cancers identified among carriers of RAD51B mutations in our cohort. This evidence concerns the gene RAD51C and triple-negative breast carcinoma.